Physicians’ perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: A questionnaire survey

다국어 초록 (Multilingual Abstract)

Background: Hyperuricemia is associated with the development and progression of chronic kidney disease (CKD) as well as cardiovascular diseases. However, there is no consistent recommendation regarding the treatment of asymptomatic hyperuricemia (AHU) in CKD patients. Here, we surveyed Korean physicians’ perceptions regarding the diagnosis and management of AHU in CKD patients.
Methods: Questionnaires on the management of AHU in CKD patients were emailed to regular members registered with the Korean Society of Nephrology.
Results: A total of 158 members answered the questionnaire. Among the respondents, 49.4%/41.1% were considered hyperuricemic in male CKD patients whereas 36.7%/20.9% were considered hyperuricemic in female CKD patients when defined by serum uric acid level over 7.0/8.0 mg/dL, respectively. A total of 80.4% reported treating AHU in CKD patients. The most important reasons to treat AHU in CKD patients were renal function preservation followed by cerebro-cardiac protection. Majority of respondents (59.5%) thought that uric acid-lowering agents (ULAs) were the most effective method for controlling serum uric acid levels. Approximately 80% chose febuxostat as the preferred medication. A total of 32.3% and 31.0%, respectively, initiated ULA treatment if the serumuric acid level was more than 8.0 or 9.0 mg/dL, respectively. In addition, 39.2% and 30.4% answered that target serum uric acid levels of less than 6.0 or 7.0 mg/dL, respectively, were appropriate. The two major hurdles to prescribing ULAs were concerns of adverse reactions and the existing lack of evidence (i.e., the absence of Korean guidelines).
Conclusion: Most Korean physicians treat AHU in CKD patients to prevent CKD progression and cerebrocardiovascular complications.

참고문헌 (Reference)

1 Wada T, "Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia : a randomized, doubleblind, placebo-controlled, parallel-group study(UPWARD study)" 22 : 860-870, 2018

2 Maahs DM, "Uric acid lowering to prevent kidney function loss in diabetes : the preventing early renal function loss(PERL)allopurinol study" 13 : 550-559, 2013

3 Srivastava A, "Uric acid and the risks of kidney failure and death in individuals with CKD" 71 : 362-370, 2018

4 Ramirez MEG, "Treatment of asymptomatic hyperuricemia in chronic kidney disease : a new target in an old enemy-a review" 8 : 551-554, 2017

5 Akasaka H, "The impact of elevation of serum uric acid level on the natural history of glomerular filtration rate(GFR)and its sex difference" 29 : 1932-1939, 2014

6 Krishnan E., "Reduced glomerular function and prevalence of gout : NHANES 2009-10" 7 : e50046-, 2012

7 Jung Soo Song, "Recent advances in management of gout" Korean Medical Association (KAMJE) 59 (59): 379-, 2016

8 Lee JH, "Prevalence of hypouricaemia and SLC22A12 mutations in healthy Korean subjects" 13 : 661-666, 2008

9 Kim Y, "Prevalence of hyperuricemia and its associated factors in the general Korean population : an analysis of a population-based nationally representative sample" 37 : 2529-2538, 2018

10 Nakaya I, "Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists:a questionnaire survey" 16 : 518-521, 2011

11 Takir M, "Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia" 63 : 924-929, 2015

12 Li L, "Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? : a systematic review and meta-analysis based on observational cohort studies" 15 : 122-, 2014

13 Kimura K, "Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia : a randomized trial" 72 : 798-810, 2018

14 Kojima S, "Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy" 40 : 1778-1786, 2019

15 Yamanaka H, "Essence of the revised guideline for the management of hyperuricemia and gout" 55 : 324-329, 2012

16 Sircar D, "Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia : a 6-month, double-blind, randomized, placebo-controlled trial" 66 : 945-950, 2015

17 Pagonas N, "Effects of treatment of asymptomatic hyperuricemia on graft survival and mortality in kidney transplant recipients" 21 : 350-359, 2016

18 Osadchuk L, "Effect of allopurinol on slowing allograft functional decline in kidney transplant recipients" 12 : 190-194, 2014

19 "Australian New Zealand Clinical Trials Registry" Australian New Zealand Clinical Trials Registry

20 Kuwabara M, "Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases : five-year Japanese cohort study" 69 : 1036-1044, 2017

21 Eleftheriadis T, "Asymptomatic hyperuricemia and chronic kidney disease : narrative review of a treatment controversial" 8 : 555-560, 2017

22 Kawashima M, "Association between asymptomatic hyperuricemia and newonset chronic kidney disease in Japanese male workers : a long-term retrospective cohort study" 12 : 31-, 2011

23 Schlesinger N, "A survey of current evaluation and treatment of gout" 33 : 2050-2052, 2006

24 Perez-Ruiz F, "A review of uric acid, crystal deposition disease, and gout" 32 : 31-41, 2015

25 Kanbay M, "A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function" 6 : 1887-1894, 2011

26 Ryu S, "A cohort study of hyperuricemia in middle-aged South Korean men" 175 : 133-143, 2012